ANIK · Anika Therapeutics, Inc. · Financials

$21.55 +0.20 (+0.94%) At close · Oct 28 Q2 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Customer concentration — top customer 53% of revenue

One customer — 53% of revenue (the three-months ended June 30, 2026)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the six-months ended June 30, 2026)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the six-months ended June 30, 2025)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the three-months ended June 30, 2025)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

View the 10-Q filed Jul 29, 2026

Market Cap

$288.40M

13.38M

Volume · Oct 28 97.79K Avg daily vol (3M) 110K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$112.82M -5.9%

FY2025

Net Income

-$10.88M +80.7%

FY2025

Gross Margin

56.56% -6.8pp

FY2025

Operating Margin

-9.8% -5.6pp

FY2025

Diluted EPS

-$0.76 +80.2%

FY2025

Operating Cash Flow

$11.19M +107.1%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Revenue	-0.3%	-2.9%	+2.0%	$114M – $122.5M	$120.65M	$112.82M	$119.91M^G	$120.79M^G	$113.83M	$147.79M	$130.46M	$114.61M	$105.56M	$113.42M	$103.38M	$93M	$105.6M	$75.08M	$71.36M	$64.78M	$55.56M	$40.14M
Cost of Revenue	+6.5%	-4.4%	+8.8%	—	$45.65M	$49.01M	$43.91M	$38.26M	$40.61M	$64.85M	$61.43M	$28.75M	$31.28M	$27.36M	$24.03M	$21.05M	$20.93M	$22.77M	$28.99M	$26.78M	$23.83M	$13.67M
Gross Profit	-4.5%	-1.6%	-1.2%	—	$75M	$63.81M	$76M	$82.53M	$73.22M	$82.94M	$69.03M	$85.86M	$74.28M	$86.06M^d	$79.35M^d	$71.95M^d	$84.67M^d	$52.32M^d	$42.37M^d	$37.99M^d	$31.73M^d	$26.47M^d
Gross Margin	—	—	—	—	—	56.56%	63.38%	68.33%	64.33%	56.12%	52.91%	74.92%	70.37%	75.87%^d	76.76%^d	77.36%^d	80.18%^d	69.68%^d	59.38%^d	58.65%^d	57.11%^d	65.94%^d
Research & Development	+12.0%	+1.9%	+11.1%	—	$27.45M	$25.77M	$25.54M	$21.76M	$18.32M	$27.33M	$23.43M	$16.67M	$18.19M	$18.79M	$10.73M	$8.99M	$8.14M	$7.06M	$5.39M	$6.17M	$6.87M	$8.18M
Selling, General & Administrative	-1.4%	-4.0%	+12.7%	—	$52.67M	$49.09M	$55.56M	$59.93M	$51.23M	$74.1M	$60.06M	$34.95M	$34.34M	$21.54M	$18.01M	$14.83M	$15.07M	$12.94M	$14.73M	$17.86M	$17.32M	$10.55M
Amortization of Intangibles	-12.6%	-44.2%	-9.6%	—	—	$400K	$700K	$600K	$600K	$7.8M	$7.4M	$1M	$1M	$1M	$1.1M	$1.1M	$2.1M	$2.1M	$2.03M	$2.19M	—	—
Depreciation & Amortization	-7.1%	-2.5%	+3.6%	—	$5.62M	$5.37M	$6.88M	$6.43M	$6.7M	$6.48M	$6.08M	$4.96M	$5.91M	$4.29M	$3.73M	$3.78M	$4.71M	$4.77M	$4.53M	$4M	$3.32M	$1.29M
Restructuring Charges	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-$286.84K	$2.54M	—	—	—
Total Costs & Expenses	+2.5%	-5.1%	+5.3%	—	$80.13M	$74.86M	$81.1M	$81.69M	$69.55M	$80.33M	$97.35M	$51.62M	$52.53M	$67.69M	$52.77M	$44.87M	$44.15M	$42.47M	$51.64M	$50.81M	$48.02M	$34.55M
Operating Income	—	—	—	—	-$5.12M	-$11.05M	-$5.1M	$844K	$3.67M	$2.62M	-$28.32M	$34.25M	$21.75M	$45.73M	$50.61M	$48.13M	$61.45M	$32.61M	$19.72M	$13.97M	$7.54M	$5.59M
Operating Margin	—	—	—	—	—	-9.8%	-4.25%	0.7%	3.22%	1.77%	-21.71%	29.88%	20.6%	40.32%	48.95%	51.76%	58.19%	43.43%	27.63%	21.56%	13.57%	13.92%
EBITDA	—	—	—	—	$500K	-$5.68M	$1.78M	$7.28M	$10.37M	$9.1M	-$22.24M	$39.21M	$27.66M	$50.02M	$54.34M	$51.91M	$66.15M	$37.38M	$24.24M	$17.97M	$10.86M	$6.88M
Investment Income (Loss)	—	—	—	—	—	—	—	—	—	—	-$13K	$25K	$371K	—	—	—	—	—	—	—	—	—
Pretax Income	—	—	—	—	-$2.91M	-$9.31M	-$2.76M	$3.16M	$4.32M	$2.43M	-$28.62M	$36.12M	$23.21M	$46.2M	$50.87M	$48.25M	$61.51M	$32.48M	$19.53M	$13.79M	$7.34M	$5.51M
Income Tax	-31.9%	—	-27.8%	—	$208K	$672K	$6.06M	$6.6M	$2.12M	-$1.71M	-$4.64M	$8.93M	$4.49M	$14.39M	$18.32M	$17.5M	$23.19M	$11.91M	$7.77M	$5.32M	$3.03M	$1.82M
Net Income	—	—	—	—	-$3.78M	-$10.88M	-$56.39M	-$82.67M	-$14.86M	$4.13M	-$23.98M	$27.19M	$18.72M	$31.82M	$32.55M	$30.76M	$38.32M	$20.58M	$11.76M	$8.47M	$4.32M	$3.69M
Net Margin	—	—	—	—	—	-9.64%	-47.02%	-68.44%	-13.05%	2.8%	-18.38%	23.73%	17.74%	28.05%	31.48%	33.07%	36.29%	27.4%	16.48%	13.07%	7.77%	9.19%
Comprehensive Income	—	—	—	—	-$4.36M	-$9.06M	-$57.23M	-$82.17M	-$15.58M	$2.96M	-$22.63M	$26.82M	$17.98M	$34.35M	$31.88M	$28.6M	$35.52M	$21.53M	$12.17M	$7.95M	$1.77M	$3.69M
EPS (Basic) USD/shares	—	—	—	—	-$0.26	-$0.76	-$3.83	-$5.64	-$1.02	$0.29	-$1.69	$1.93	$1.30	$2.18	$2.22	$2.06	$2.61	$1.46	$0.89	$0.65	$0.34	$0.32
EPS (Diluted) USD/shares	—	—	—	—	-$0.27	-$0.76	-$3.83	-$5.64	-$1.02	$0.28	-$1.69	$1.89	$1.27	$2.11	$2.15	$2.01	$2.51	$1.39	$0.82	$0.62	$0.32	$0.32
Shares Outstanding (Basic Avg) shares	-0.5%	+0.2%	-0.4%	—	—	14.34M	14.72M	14.66M	14.56M	14.4M	14.22M	14.12M	14.44M	14.58M	14.68M	14.93M	14.68M	14.09M	13.26M	13.06M	12.62M	11.39M
Shares Outstanding (Diluted Avg) shares	-1.0%	+0.2%	-0.7%	—	—	14.34M	14.72M	14.66M	14.79M	14.63M	14.22M	14.37M	14.69M	15.07M	15.12M	15.32M	15.27M	14.83M	14.34M	13.75M	13.65M	11.56M

^d Gross profit for periods the company did not report it, or tagged its operating income as gross profit, is Revenue − Cost of Revenue. Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $110.4M in buybacks.

Debt Profile

Completed filing coverage through Jul 14, 2026

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Current operating lease liabilities	2026-06-30	USD 1,935,000	10-Q filed 2026-07-29
Noncurrent operating lease liabilities	2026-06-30	USD 23,315,000	10-Q filed 2026-07-29

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 1.82×

EV/EBIT

—

Peer median 13.50×

P/E (TTM)

—

Peer median 15.38×

Peer medians compare against the 50 similar-size Drug Manufacturers - Specialty & Generic companies (of 101 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$70,058,000	$82,446,000	$86,911,000	$83,746,000	$113,833,000	$103,182,000	$90,302,000	$85,351,000
Europe	$22,214,000	$19,403,000	$17,313,000	$17,227,000	$19,580,000	$14,179,000	$14,744,000	$11,730,000
Other Location	$20,547,000	$18,058,000	$16,568,000	$12,854,000	$14,381,000	$13,096,000	$9,564,000	$8,474,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
OEM Channel	$64,406,000	$77,770,000	$84,645,000	$81,675,000	—	—	—	—
Commercial Channel	$48,413,000	$42,137,000	$36,147,000	$32,152,000	—	—	—	—
Joint Preservation and Restoration	—	—	—	—	$48,588,000	$39,368,000	$2,070,000	$1,127,000
Licensing Milestone and Contract Revenue	—	—	—	—	—	—	$98,000	—
Nonorthopedic	—	—	—	—	$14,122,000	$8,060,000	$8,976,000	$7,685,000
OA Pain Management	—	—	—	—	$85,084,000	$83,029,000	$103,466,000	$96,719,000
Service	—	—	—	—	—	—	$98,000	$24,000

Key facts CIK 898437 CUSIP 035255108 13F (30d) 25 filings 25 filers Visit website Investor relations